In successive in vivo psoriasis imiquimod (IMQ)-induced murine experiments, the EVs significantly reduced the typical psoriatic symptoms like acanthosis as well as suppressing the over-active immune reaction, pointed out by the IL-17 release and Th17 expansion (41). Here, IL17A is linked to psoriasis.